Market Exclusive

Analyst Activity – CIBC Raises Its Price Target On Cipher Pharmaceuticals (TSE:CPH) to C$7.50

Analyst Ratings For Cipher Pharmaceuticals (TSE:CPH)

Today, CIBC raised its price target on Cipher Pharmaceuticals (TSE:CPH) to C$7.50 per share.

There are 3 hold ratings on the stock.

The current consensus rating on Cipher Pharmaceuticals (TSE:CPH) is Hold (Score: 2.00) with a consensus target price of C$6.13 per share, a potential .

Some recent analyst ratings include


About Cipher Pharmaceuticals (TSE:CPH)
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Recent Trading Activity for Cipher Pharmaceuticals (TSE:CPH)
Shares of Cipher Pharmaceuticals closed the previous trading session at 4.92 up +0.25 5.35% with 41,579 shares trading hands.

Exit mobile version